Drug:
Reaction: PRODUCT USE ISSUE
20260101 - 20261231
No. 201 - 300
| No. | safetyreportid |
occurcountry |
patientonsetage |
patientsex 1:M 2:F |
|---|---|---|---|---|
Adverse reaction |
||||
Drug (openfda.generic_name, medicinalproduct) |
||||
| 201 | 26534802 |
US |
66 | 2 |
Sepsis, Product use issue, Upper limb fracture, Osteoporosis, Lung neoplasm, Hyperhidrosis, Nausea, |
||||
VORTIOXETINE, |
||||
| 202 | 26534928 |
SG |
1 | |
Disease progression, Product use issue, |
||||
DAROLUTAMIDE, |
||||
| 203 | 26535055 |
US |
69 | |
Product use issue, Device mechanical issue, Device malfunction, |
||||
FLUTICASONE PROPIONATE AND SALMETEROL, |
||||
| 204 | 26535130 |
CN |
1 | |
Acute kidney injury, Hepatitis acute, Cholecystitis, Pancreatitis, Product use issue, |
||||
SEMAGLUTIDE, |
||||
| 205 | 26535194 |
US |
59 | 2 |
Hypertension, COVID-19, Impaired gastric emptying, Metabolic disorder, Postprandial hypoglycaemia, Illness, Body temperature decreased, Vomiting, Alopecia, Dehydration, Headache, Blood glucose increased, Autoimmune disorder, Antinuclear antibody positive, Psoriasis, Sinusitis, Influenza, Dumping syndrome, Inappropriate schedule of product administration, Therapeutic response decreased, Overdose, Drug ineffective, Product use issue, |
||||
IXEKIZUMAB, IXEKIZUMAB, IXEKIZUMAB, IXEKIZUMAB, TIRZEPATIDE, DULAGLUTIDE, LIRAGLUTIDE, |
||||
| 206 | 26535411 |
EU |
69 | 2 |
Neutropenia, Anaemia, Infection, Product use issue, Toxicity to various agents, |
||||
IVOSIDENIB, AZACITIDINE, AZACITIDINE FOR, AZACITIDINE, AZACITIDINE FOR, |
||||
| 207 | 26526828 |
EU |
81 | 2 |
Cardiac failure, Hyponatraemia, Rib fracture, Hip fracture, Product use issue, Fall, Multiple fractures, |
||||
DEXAMETHASONE, DEXAMETHASONE 1.5 MG, SELINEXOR, POMALIDOMIDE, |
||||
| 208 | 26526839 |
US |
1 | |
Product use issue, |
||||
PIMAVANSERIN TARTRATE, |
||||
| 209 | 26526952 |
US |
48 | 2 |
Product use issue, |
||||
LENALIDOMIDE, |
||||
| 210 | 26527057 |
EU |
1 | |
Product dose omission issue, Product use issue, Device issue, Liquid product physical issue, |
||||
TEZEPELUMAB-EKKO, TEZEPELUMAB-EKKO, |
||||
| 211 | 26527125 |
US |
26 | 2 |
Product use issue, |
||||
VIMSELTINIB, |
||||
| 212 | 26527182 |
US |
||
Product use issue, Product dose omission issue, Product cleaning inadequate, Device use issue, Dyspnoea, |
||||
| 213 | 26527236 |
JP |
||
Dysphagia, Product use issue, |
||||
OSIMERTINIB, |
||||
| 214 | 26527246 |
CA |
45 | 1 |
Aspiration, Disseminated tuberculosis, Enteral nutrition, Gastrostomy, Hepatic enzyme increased, Intentional dose omission, Intercepted product prescribing error, Meningitis tuberculous, Pneumothorax, Product use issue, Surgical vascular shunt, Tracheostomy, Tuberculosis of central nervous system, Weaning failure, |
||||
ADALIMUMAB, ADALIMUMAB-AATY, ADALIMUMAB-ADAZ, ADALIMUMAB-FKJP, ADALIMUMAB, ADALIMUMAB-AATY, ADALIMUMAB-ADAZ, ADALIMUMAB-FKJP, ADALIMUMAB, ADALIMUMAB-AATY, ADALIMUMAB-ADAZ, ADALIMUMAB-FKJP, METFORMIN, METFORMIN ER 500 MG, METFORMIN ER 750 MG, |
||||
| 215 | 26527405 |
US |
1 | |
Bronchitis, Product use issue, |
||||
DAPAGLIFLOZIN, |
||||
| 216 | 26527589 |
CA |
65 | 2 |
Abdominal pain, Alanine aminotransferase increased, Arthralgia, Arthritis, Arthropathy, Aspartate aminotransferase increased, Basal cell carcinoma, Blood parathyroid hormone decreased, Breath sounds abnormal, C-reactive protein increased, Condition aggravated, Drug eruption, Drug hypersensitivity, Drug intolerance, Drug tolerance decreased, Erythema, Granuloma skin, Headache, Hepatic enzyme increased, Hypercalcaemia, Hypersensitivity, Hypertension, Inflammation, Infusion related reaction, Insomnia, Joint swelling, Musculoskeletal stiffness, Pain, Panniculitis, Peripheral swelling, Pneumonia, Pruritus, Pulmonary fibrosis, Rash, Rash pruritic, Red blood cell sedimentation rate increased, Rheumatoid arthritis, Rheumatoid factor positive, Rheumatoid nodule, Skin necrosis, Skin ulcer, Synovitis, Ulcer, Deafness, Contraindicated product administered, Prescribed underdose, Product use issue, Product use in unapproved indication, Adverse event, Off label use, Treatment failure, Therapeutic product effect decreased, Therapeutic response decreased, Drug ineffective, |
||||
BUDESONIDE, HYDROXYCHLOROQUINE, HYDROXYCHLOROQUINE, HYDROXYCHLOROQUINE, HYDROXYCHLOROQUINE, HYDROXYCHLOROQUINE, HYDROXYCHLOROQUINE, HYDROXYCHLOROQUINE, HYDROXYCHLOROQUINE, HYDROXYCHLOROQUINE SULFATE, HYDROXYCHLOROQUINE SULFATE, HYDROXYCHLOROQUINE SULFATE, HYDROXYCHLOROQUINE SULFATE, HYDROXYCHLOROQUINE SULFATE, HYDROXYCHLOROQUINE SULFATE, HYDROXYCHLOROQUINE SULFATE, HYDROXYCHLOROQUINE SULFATE, HYDROXYCHLOROQUINE SULFATE, HYDROXYCHLOROQUINE SULFATE, HYDROXYCHLOROQUINE SULFATE, HYDROXYCHLOROQUINE SULFATE, HYDROXYCHLOROQUINE SULFATE, LEFLUNOMIDE, LEFLUNOMIDE, LEFLUNOMIDE, LEFLUNOMIDE, LEFLUNOMIDE, LEFLUNOMIDE, METHOTREXATE, METHOTREXATE SODIUM, METHOTREXATE, METHOTREXATE SODIUM, METHOTREXATE, METHOTREXATE SODIUM, METHOTREXATE, METHOTREXATE SODIUM, METHOTREXATE, METHOTREXATE SODIUM, METHOTREXATE, METHOTREXATE SODIUM, METHOTREXATE, METHOTREXATE SODIUM, METHOTREXATE, METHOTREXATE SODIUM, RITUXIMAB, RITUXIMAB, RITUXIMAB, RITUXIMAB, RITUXIMAB, RITUXIMAB, RITUXIMAB, RITUXIMAB, RITUXIMAB, RITUXIMAB, RITUXIMAB, RITUXIMAB, SULFASALAZINE, CYCLOSPORINE, AZATHIOPRINE, AZATHIOPRINE, AZATHIOPRINE, TOCILIZUMAB, TOCILIZUMAB, TOCILIZUMAB, TOCILIZUMAB, TOCILIZUMAB, TOCILIZUMAB, TOCILIZUMAB, TOCILIZUMAB, TOCILIZUMAB, TOCILIZUMAB, TOCILIZUMAB, TOCILIZUMAB, TOCILIZUMAB, TOCILIZUMAB, TOCILIZUMAB, TOCILIZUMAB, TOCILIZUMAB, LEFLUNOMIDE, LEFLUNOMIDE, LEFLUNOMIDE, LEFLUNOMIDE, LEFLUNOMIDE, LEFLUNOMIDE, ADALIMUMAB, ADALIMUMAB, ADALIMUMAB, LEFLUNOMIDE, LEFLUNOMIDE, LEFLUNOMIDE, LEFLUNOMIDE, ALENDRONATE SODIUM, MAGNESIUM OXIDE, ABATACEPT, ABATACEPT, ABATACEPT, ABATACEPT, ABATACEPT, ABATACEPT, ABATACEPT, ABATACEPT, ABATACEPT, ABATACEPT, HYDROXYCHLOROQUINE SULFATE, HYDROXYCHLOROQUINE SULFATE, INFLIXIMAB, INFLIXIMAB, INFLIXIMAB, INFLIXIMAB, INFLIXIMAB, INFLIXIMAB, INFLIXIMAB, INFLIXIMAB, TOFACITINIB, IXEKIZUMAB, SECUKINUMAB, IRON, ALENDRONATE SODIUM, ALPRAZOLAM, AMLODIPINE BESYLATE, ATENOLOL, BISOPROLOL FUMARATE, CELECOXIB, CYANOCOBALAMIN, ERGOCALCIFEROL, ESOMEPRAZOLE, ESOMEPRAZOLE MAGNESIUM, ESOMEPRAZOLE MAGNESIUM CAPSULE, DELAYED RELEASE, ESOMEPRAZOLE MAGNESIUM DIHYDRATE, ESOMEPRAZOLE MAGNESIUM DELAYED RELEASE CAPSULES, FOLIC ACID, GOLD, HYDROCHLOROTHIAZIDE, IRON SUCROSE, PREGABALIN, METFORMIN, METFORMIN ER 500 MG, METFORMIN ER 750 MG, MORPHINE SULFATE, PANTOPRAZOLE SODIUM, PANTOPRAZOLE, PANTOPRAZOLE SODIUM IN 0.9% SODIUM CHLORIDE, PANTOPRAZOLE SODIUM INJECTION, PAROXETINE HYDROCHLORIDE, PRAMIPEXOLE DIHYDROCHLORIDE, PREDNISONE, PREDNISONE, PREDNISONE, PREDNISONE, PREDNISONE, PREDNISONE, PROPRANOLOL HYDROCHLORIDE, RAMIPRIL, RISEDRONATE SODIUM, SERTRALINE HYDROCHLORIDE, GOLIMUMAB, TELMISARTAN, SIMVASTATIN, |
||||
| 217 | 26527591 |
CA |
63 | 2 |
Erythema, Pruritus, Anxiety, Chest discomfort, Hot flush, Hypotension, Hyperventilation, Malaise, Product use issue, |
||||
INFLIXIMAB, ACETAMINOPHEN, GUAIFENESIN, AND PHENYLEPHRINE HYDROCHLORIDE, ACETAMINOPHEN, |
||||
| 218 | 26527877 |
US |
17 | 1 |
No adverse event, Product use issue, Circumstance or information capable of leading to medication error, Product physical issue, |
||||
LISDEXAMFETAMINE DIMESYLATE, |
||||
| 219 | 26527899 |
US |
54 | 2 |
Headache, Nausea, Dizziness, Product use issue, Device information output issue, Device malfunction, Device infusion issue, Product leakage, |
||||
TREPROSTINIL, TREPROSTINIL, ERGOCALCIFEROL, SODIUM CHLORIDE, SODIUM CHLORIDE TABLET, SODIUM CHLORIDE TABLETS, FAMOTIDINE, VITAMIN C, METOLAZONE, ACETAMINOPHEN, GUAIFENESIN, AND PHENYLEPHRINE HYDROCHLORIDE, ACETAMINOPHEN, ZINC, ZINC GLUCONATE, ZINC CHLORIDE, TADALAFIL, FUROSEMIDE, OMEPRAZOLE, OMEPRAZOLE MAGNESIUM, MACITENTAN, SOTATERCEPT-CSRK, OXYGEN, 0XYGEN, IRON, IPRATROPIUM BROMIDE, ASPIRIN, ASPIRIN 81 MG, ASPIRIN 325 MG, GABAPENTIN, AZITHROMYCIN, AZITHROMYCIN MONOHYDRATE, AZITHROMYCIN DIHYDRATE, BENZONATATE, LORATADINE, LORATADINE ORAL, ONDANSETRON HYDROCHLORIDE, |
||||
| 220 | 26528135 |
US |
2 | |
Cough, Product dose omission issue, Device delivery system issue, Product packaging quantity issue, Product use issue, Wrong technique in product usage process, |
||||
ALBUTEROL SULFATE, |
||||
| 221 | 26528245 |
US |
4 | |
Urticaria, Product use issue, |
||||
CETIRIZINE, CETIRIZINE HYDROCHLORIDE, CETIIRIZINE, LEVALBUTEROL, LEVALBUTEROL HYDROCHLORIDE, DORNASE ALFA, BUDESONIDE AND FORMOTEROL FUMARATE DIHYDRATE, TOBRAMYCIN, TOBRAMYCIN SULFATE, TOBRAMYCIN SOLUTION, PANCRELIPASE LIPASE, PANCRELIPASE PROTEASE, PANCRELIPASE AMYLASE, ZINC, ZINC GLUCONATE, ZINC CHLORIDE, |
||||
| 222 | 26528579 |
2 | ||
Hyperammonaemia, Mental status changes, Product use issue, Inappropriate schedule of product administration, |
||||
TESTOSTERONE UNDECANOATE, TESTOSTERONE UNDECANOATE, TESTOSTERONE UNDECANOATE, TESTOSTERONE UNDECANOATE, TESTOSTERONE UNDECANOATE, |
||||
| 223 | 26528715 |
1 | ||
Haematological infection, Product use issue, |
||||
MOMELOTINIB, |
||||
| 224 | 26528823 |
US |
||
Product dose omission issue, Off label use, Product use issue, |
||||
LENALIDOMIDE, |
||||
| 225 | 26528840 |
EU |
22 | 2 |
Abdominal pain, Diarrhoea, Product use issue, Product use issue, Off label use, |
||||
TRAMETINIB, TRAMETINIB, PEMBROLIZUMAB, PEMBROLIZUMAB, ENCORAFENIB, ENCORAFENIB, BINIMETINIB, BINIMETINIB, ACETAMINOPHEN, ACETAMINOPHEN 500MG, ACETAMINOPHEN TABLET EXTENDED RELEASE, PAIN RELIEVER, GABAPENTIN, QUETIAPINE, PREDNISONE, PREDNISONE, OXAZEPAM, |
||||
| 226 | 26528986 |
US |
||
Product use issue, Fatigue, |
||||
TIRZEPATIDE, |
||||
| 227 | 26529031 |
US |
||
Abdominal operation, Product use issue, |
||||
TOBRAMYCIN, |
||||
| 228 | 26529127 |
CA |
64 | 2 |
Haematological infection, Pneumonia, Oedema, Asthenia, Product use issue, Walking aid user, |
||||
INFLIXIMAB, INFLIXIMAB, INFLIXIMAB, |
||||
| 229 | 26529356 |
13 | 2 | |
Vertigo, Headache, Blood test abnormal, Vomiting, Abdominal pain, Product use issue, Intentional overdose, |
||||
ACETAMINOPHEN, ACETAMINOPHEN 500MG, ACETAMINOPHEN TABLET EXTENDED RELEASE, PAIN RELIEVER, |
||||
| 230 | 26529580 |
EU |
72 | 1 |
Acute respiratory distress syndrome, General physical condition abnormal, Interstitial lung disease, Pulmonary fibrosis, Pulmonary oedema, Hallucination, Neuropathy peripheral, Off label use, Product use issue, |
||||
PACLITAXEL, PACLITAXEL (AIBUMIN-BOUND), CARBOPLATIN, NIVOLUMAB, NIVOLUMAB, NIVOLUMAB, PREGABALIN, DESLORATADINE, CELECOXIB, ACETAMINOPHEN, ACETAMINOPHEN 500MG, ACETAMINOPHEN TABLET EXTENDED RELEASE, PAIN RELIEVER, ACETAMINOPHEN, ACETAMINOPHEN 500MG, ACETAMINOPHEN TABLET EXTENDED RELEASE, PAIN RELIEVER, CANDESARTAN, AMLODIPINE, SODIUM CHLORIDE, SODIUM CHLORIDE TABLET, SODIUM CHLORIDE TABLETS, SODIUM CHLORIDE, SODIUM CHLORIDE TABLET, SODIUM CHLORIDE TABLETS, NOREPINEPHRINE (BITARTRATE), NOREPINEPHRINE BITARTRATE, ESOMEPRAZOLE, ESOMEPRAZOLE MAGNESIUM, ESOMEPRAZOLE MAGNESIUM CAPSULE, DELAYED RELEASE, ESOMEPRAZOLE MAGNESIUM DIHYDRATE, ESOMEPRAZOLE MAGNESIUM DELAYED RELEASE CAPSULES, CELECOXIB, FUROSEMIDE, SPIRONOLACTONE, |
||||
| 231 | 26529607 |
US |
62 | 2 |
Diarrhoea, Nausea, Dizziness, Depression, Therapeutic product effect decreased, Mood altered, Abdominal pain upper, Restlessness, Vomiting, Insomnia, Inappropriate schedule of product administration, Product use issue, |
||||
DEUTETRABENAZINE, DEUTETRABENAZINE, CETIRIZINE, CETIRIZINE HYDROCHLORIDE, CETIIRIZINE, AMLODIPINE, ARIPIPRAZOLE, QUETIAPINE, |
||||
| 232 | 26529621 |
US |
60 | 1 |
Product use issue, |
||||
MAVACAMTEN, |
||||
| 233 | 26529689 |
US |
73 | 1 |
Adverse event, Product use issue, |
||||
| 234 | 26529732 |
US |
84 | 2 |
Dizziness, Fall, Product use issue, |
||||
MAVACAMTEN, |
||||
| 235 | 26529921 |
US |
51 | 2 |
Product use issue, Incorrect dose administered, |
||||
TIRZEPATIDE, |
||||
| 236 | 26530174 |
US |
72 | 2 |
Cardiomyopathy, Pancreatitis, Hyperhidrosis, Product use issue, Discharge, Obstruction, Heart valve incompetence, Spleen disorder, |
||||
TEDUGLUTIDE, TEDUGLUTIDE, TEDUGLUTIDE, TEDUGLUTIDE, TEDUGLUTIDE, |
||||
| 237 | 26530353 |
US |
69 | 1 |
Balance disorder, Fall, Head injury, Haematological infection, Atrial fibrillation, Product use issue, |
||||
SEMAGLUTIDE, SEMAGLUTIDE, |
||||
| 238 | 26530515 |
US |
66 | 2 |
Glycosylated haemoglobin increased, Product dose omission issue, Inability to afford medication, Insurance issue, Product use issue, |
||||
SITAGLIPTIN, EMPAGLIFLOZIN, AMLODIPINE, CALCITRIOL, CALCITRIOL CAPSULES 0.25 MCG, CALCITRIOL CAPSULES 0.5 MCG, |
||||
| 239 | 26530612 |
CA |
2 | |
Product use issue, Electrocardiogram QT prolonged, Schizoaffective disorder, Sinus rhythm, Insomnia, |
||||
ESTRADIOL, ERGOCALCIFEROL, VALPROIC ACID, CONJUGATED ESTROGENS, ESTROGENS, CONJUGATED, CLOZAPINE, CLOZAPINE, CLOZAPINE, CLOZAPINE, OLANZAPINE, OLANZAPINE, OLANZAPINE, OLANZAPINE, OLANZAPINE, ARIPIPRAZOLE ORALLY DISINTEGRATING, ARIPIPRAZOLE, ARIPIPRAZOLE ORAL, RANITIDINE, RANITIDINE, RANITIDINE, DIVALPROEX SODIUM, DIVALPROEX SODIUM, DIVALPROEX SODIUM, DIVALPROEX SODIUM, ACETAMINOPHEN AND CAFFEINE, ACETAMINOPHEN AND CAFFEINE, ACETAMINOPHEN AND CAFFEINE, AMLODIPINE, ACETAMINOPHEN, ACETAMINOPHEN 500MG, ACETAMINOPHEN TABLET EXTENDED RELEASE, PAIN RELIEVER, ACETAMINOPHEN, ACETAMINOPHEN 500MG, ACETAMINOPHEN TABLET EXTENDED RELEASE, PAIN RELIEVER, BREXPIPRAZOLE, ESTRADIOL, ESTRADIOL GEL 0.1%, ESTRADIOL TRANSDERMAL, ESTRADIOL,, ACETAMINOPHEN, ACETAMINOPHEN 500MG, ACETAMINOPHEN TABLET EXTENDED RELEASE, PAIN RELIEVER, ACETAMINOPHEN, ACETAMINOPHEN 500MG, ACETAMINOPHEN TABLET EXTENDED RELEASE, PAIN RELIEVER, BREXPIPRAZOLE, BREXPIPRAZOLE, CLOTRIMAZOLE, DRS. CLOTRIMAZOLE, FAMILY WELLNESS CLOTRIMAZOLE, CLOTRIMAZOLE TOPICAL, ALUMINUM HYDROXIDE, CONJUGATED ESTROGENS, ESTROGENS, CONJUGATED, LEVOTHYROXINE SODIUM, LEVOTHYROXINE SODIUM ANHYDROUS, ARIPIPRAZOLE ORALLY DISINTEGRATING, ARIPIPRAZOLE, ARIPIPRAZOLE ORAL, VALPROATE SODIUM, PHENYLEPHRINE HYDROCHLORIDE, |
||||
| 240 | 26530685 |
US |
2 | |
Cardiac failure congestive, Product dose omission issue, Product use issue, |
||||
DAPAGLIFLOZIN, |
||||
| 241 | 26530690 |
US |
87 | 1 |
Off label use, Product use issue, |
||||
NIRMATRELVIR AND RITONAVIR, |
||||
| 242 | 26530830 |
CA |
44 | 2 |
Abdominal pain upper, Asthenia, Back pain, Body temperature increased, Diarrhoea, Ear pain, Headache, Insomnia, Muscle spasticity, Night sweats, Respiratory disorder, Stomatitis, Urticaria, Vomiting, Contraindicated product administered, Drug ineffective, Drug intolerance, Intentional product use issue, Medication error, Maternal exposure timing unspecified, Off label use, Product use issue, Therapeutic product effect decreased, Treatment failure, |
||||
OXYCODONE HYDROCHLORIDE, OXYCODONE, CORTISONE ACETATE, CORTISONE ACETATE, DICLOFENAC POTASSIUM, DICLOFENAC POTASSIUM, FILM COATED, DICLOFENAC POTASSIUM TABLETS, HYDROCORTISONE ACETATE, HYDROXYCHLOROQUINE, HYDROXYCHLOROQUINE, HYDROXYCHLOROQUINE, HYDROXYCHLOROQUINE, INFLIXIMAB, ISOPROPYL ALCOHOL, 70%ISOPROPYL ALCOHOL, ALCOHOL PREP PADS, ALCOHOL, ISOPROPYL ALCOHOL SPRAY, METHOTREXATE, METHOTREXATE SODIUM, METHOTREXATE, METHOTREXATE SODIUM, METHOTREXATE, METHOTREXATE SODIUM, METHOTREXATE, METHOTREXATE SODIUM, METHOTREXATE, METHOTREXATE SODIUM, METHOTREXATE, METHOTREXATE SODIUM, METHOTREXATE, METHOTREXATE SODIUM, METHOTREXATE, METHOTREXATE SODIUM, METHOTREXATE, METHOTREXATE SODIUM, OXYCODONE HYDROCHLORIDE AND ACETAMINOPHEN, HYDROXYCHLOROQUINE SULFATE, HYDROXYCHLOROQUINE SULFATE, RITUXIMAB, TOFACITINIB, TRIAMCINOLONE ACETONIDE, TRIAMCINOLONE ACETONIDE OINTMENT USP, 0.05%, ACETAMINOPHEN, ACETAMINOPHEN 500MG, ACETAMINOPHEN TABLET EXTENDED RELEASE, PAIN RELIEVER, PANTOPRAZOLE SODIUM, PANTOPRAZOLE, PANTOPRAZOLE SODIUM IN 0.9% SODIUM CHLORIDE, PANTOPRAZOLE SODIUM INJECTION, SULFAMETHOXAZOLE AND TRIMETHOPRIM, ACETAMINOPHEN, GUAIFENESIN, AND PHENYLEPHRINE HYDROCHLORIDE, ACETAMINOPHEN, |
||||
| 243 | 26531057 |
US |
2 | |
Pain in extremity, Product use issue, Wrong technique in product usage process, Product container issue, |
||||
LATANOPROST, |
||||
| 244 | 26522697 |
US |
1 | |
Condition aggravated, Product use issue, |
||||
PIMAVANSERIN TARTRATE, |
||||
| 245 | 26522745 |
US |
78 | 2 |
Product use issue, |
||||
RIPRETINIB, |
||||
| 246 | 26522909 |
US |
1 | |
Product use issue, |
||||
PIMAVANSERIN TARTRATE, |
||||
| 247 | 26522917 |
US |
68 | 2 |
Product use issue, Dyspepsia, |
||||
TIRZEPATIDE, |
||||
| 248 | 26522965 |
US |
1 | |
Product dose omission issue, Product use issue, No adverse event, |
||||
SITAGLIPTIN, |
||||
| 249 | 26523031 |
US |
||
No adverse event, Product use issue, |
||||
VORTIOXETINE, |
||||
| 250 | 26523140 |
US |
||
Product use issue, |
||||
ISOTRETINOIN, |
||||
| 251 | 26523142 |
US |
||
Product use issue, |
||||
ISOTRETINOIN, |
||||
| 252 | 26523273 |
CA |
43 | 2 |
Sleep disorder, Sinusitis, Sciatica, Road traffic accident, Rheumatoid arthritis, Rheumatic fever, Respiratory disorder, Red blood cell sedimentation rate increased, Rectal haemorrhage, Rash, Psoriatic arthropathy, Porphyria acute, Pneumonia, Peripheral venous disease, Peripheral swelling, Pericarditis, Pemphigus, Paraesthesia, Pancreatitis, Pain in extremity, Pain, Overlap syndrome, Osteoarthritis, Onychomycosis, Onychomadesis, Oedema peripheral, Normal newborn, Obesity, Night sweats, Neck pain, Nasopharyngitis, Nail disorder, Musculoskeletal pain, Muscular weakness, Muscle spasms, Muscle injury, Mobility decreased, Migraine, Memory impairment, Lupus-like syndrome, Lung disorder, Lower respiratory tract infection, Lower limb fracture, Swelling, Liver injury, Swollen joint count increased, Synovitis, Systemic lupus erythematosus, Taste disorder, Ulcer haemorrhage, Underdose, Type 2 diabetes mellitus, Urticaria, Vomiting, Weight increased, Wheezing, White blood cell count increased, Wound, Wound infection, Abdominal discomfort, X-ray abnormal, Stomatitis, Therapeutic product effect incomplete, Treatment failure, Therapy non-responder, Therapeutic product effect decreased, Maternal exposure during pregnancy, Product use issue, Off label use, Product use in unapproved indication, Product quality issue, Prescribed underdose, |
||||
CANDESARTAN, ADALIMUMAB, ADALIMUMAB-AATY, ADALIMUMAB-ADAZ, ADALIMUMAB-FKJP, ALENDRONATE SODIUM, ALENDRONATE SODIUM, |
||||
| 253 | 26523422 |
US |
2 | |
Product use issue, Product use in unapproved indication, Product administered at inappropriate site, Intentional product misuse, |
||||
| 254 | 26524030 |
US |
42 | 2 |
Product dose omission in error, Product use issue, Product use issue, Insurance issue, |
||||
| 255 | 26524067 |
US |
2 | |
Hereditary angioedema, Product use issue, |
||||
ECALLANTIDE, ECALLANTIDE, |
||||
| 256 | 26524109 |
US |
55 | 2 |
Suicidal ideation, Depression, Impaired work ability, Product use issue, Negative thoughts, Mood altered, Pruritus, Dyskinesia, Dysphonia, |
||||
DEUTETRABENAZINE, DEUTETRABENAZINE, DEUTETRABENAZINE, VALBENAZINE, DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE, DEXTROAMPHETAMINE SULFATE, AND AMPHETAMINE SULFATE, DEXTROAMPHETAMINE SULFATE, DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE SULFATE AND AMPHETAMINE ASPARTATE, |
||||
| 257 | 26524203 |
US |
1 | |
Renal failure, Product use issue, |
||||
DAPAGLIFLOZIN, |
||||
| 258 | 26524596 |
CO |
20 | 2 |
Pyrexia, Allergy to immunoglobulin therapy, Infection, Insurance issue, Treatment noncompliance, Product use issue, Weight decreased, Body height increased, |
||||
| 259 | 26524675 |
CA |
37 | 2 |
Dyspepsia, Product use issue, |
||||
ADALIMUMAB-BWWD, |
||||
| 260 | 26524768 |
CA |
||
Migraine, Heart rate increased, Device leakage, Product use issue, Inappropriate schedule of product administration, Product knowledge deficit, |
||||
SEMAGLUTIDE, ORAL SEMAGLUTIDE, |
||||
| 261 | 26524966 |
US |
2 | |
Central nervous system lesion, Hospitalisation, Muscular weakness, Tremor, Headache, Musculoskeletal disorder, Insurance issue, Product use issue, |
||||
| 262 | 26524985 |
CA |
74 | 2 |
Acute kidney injury, Drug ineffective, Rash erythematous, Renal disorder, Renal failure, Pruritus, Respiratory failure, Back pain, Contusion, Dermatitis exfoliative generalised, Psoriasis, Pulmonary oedema, Product use issue, |
||||
METHOTREXATE, METHOTREXATE SODIUM, ACITRETIN, CYCLOSPORINE, SECUKINUMAB, SECUKINUMAB, SECUKINUMAB, SECUKINUMAB, SECUKINUMAB, SECUKINUMAB, SECUKINUMAB, SECUKINUMAB, SECUKINUMAB, SECUKINUMAB, CYCLOSPORINE, HYDROCORTISONE, ANTIPRURITIC (ANTI-ITCH), ANTI-ITCH CREAM, HYDROCORTISONE CREAM, HYDROCORTISONE 1%, HYDROCORTISONE CREAM 1%, ANTI-PRURITIC, HYDROCORTISONE CONTINUOUS SPRAY, HYDROCORTISONE LOTION, HYDROCORTISONE ACETATE, ANTI ITCH, ANTI-ITCH, COOL RELIEF GEL WITH ALOE, HYDROCORTISONE SPRAY, DRS. HYDROCORTISONE, |
||||
| 263 | 26525065 |
EU |
25 | 2 |
Furuncle, Product use issue, |
||||
OFATUMUMAB, OFATUMUMAB, |
||||
| 264 | 26525182 |
15 | 2 | |
Neutropenia, Product use in unapproved indication, Product use issue, |
||||
GANCICLOVIR SODIUM, GANCICLOVIR, GANCICLOVIR SODIUM, GANCICLOVIR, GANCICLOVIR SODIUM, GANCICLOVIR, |
||||
| 265 | 26525205 |
US |
66 | 1 |
Incontinence, Asthenia, Fall, Product use issue, Product availability issue, |
||||
RISPERIDONE, RISPERIDONE, RISPERIDONE, |
||||
| 266 | 26525610 |
US |
2 | |
Product use issue, |
||||
USTEKINUMAB, USTEKINUMAB, |
||||
| 267 | 26525635 |
US |
67 | 1 |
Hospitalisation, Product use issue, |
||||
TRIENTINE HYDROCHLORIDE, |
||||
| 268 | 26525982 |
JP |
85 | 2 |
Myocardial infarction, Product use issue, |
||||
BREXPIPRAZOLE, BREXPIPRAZOLE, |
||||
| 269 | 26526083 |
US |
76 | 2 |
Lung disorder, Product use issue, |
||||
REGORAFENIB, |
||||
| 270 | 26526129 |
37 | 2 | |
Product use issue, General physical health deterioration, |
||||
SOTATERCEPT-CSRK, |
||||
| 271 | 26526148 |
EU |
12 | 2 |
Serotonin syndrome, Neuroleptic malignant syndrome, Product use issue, |
||||
HALOPERIDOL, HALOPERIDOL LACTATE, HALOPERIDOL, HALOPERIDOL LACTATE, FLUOXETINE HYDROCHLORIDE, FLUOXETINE, FLUOXETINE HYDROCHLORIDE, FLUOXETINE, |
||||
| 272 | 26526532 |
IL |
55 | 2 |
International normalised ratio abnormal, Incorrect dose administered, Product use issue, |
||||
TIRZEPATIDE, |
||||
| 273 | 26526736 |
CA |
43 | 2 |
Systemic lupus erythematosus, Rheumatoid factor positive, Mobility decreased, Off label use, Sinusitis, Therapy non-responder, Nasopharyngitis, Wound infection, Swelling, Therapeutic product effect decreased, Treatment failure, Sciatica, Irritable bowel syndrome, Rash, Rash pruritic, Joint range of motion decreased, Prescribed overdose, Muscle injury, Intentional product use issue, Live birth, Sleep disorder, Therapeutic response decreased, Lower respiratory tract infection, Synovitis, Lower limb fracture, Maternal exposure during pregnancy, Pruritus, Nausea, Prescribed underdose, Wound, Rheumatoid arthritis, Type 2 diabetes mellitus, Wheezing, Malaise, Lupus vulgaris, Product use issue, Ulcer haemorrhage, Vomiting, |
||||
DICLOFENAC SODIUM, RITUXIMAB, SECUKINUMAB, SECUKINUMAB, CALCIUM CARBONATE, DILTIAZEM HYDROCHLORIDE, DILTIAZEM HYDROCHLORIDE EXTENDED-RELEASE TABLETS, DILTIAZEM HYDROCHLORIDE, DILTIAZEM HYDROCHLORIDE EXTENDED-RELEASE TABLETS, HYDROCORTISONE, ANTIPRURITIC (ANTI-ITCH), ANTI-ITCH CREAM, HYDROCORTISONE CREAM, HYDROCORTISONE 1%, HYDROCORTISONE CREAM 1%, ANTI-PRURITIC, HYDROCORTISONE CONTINUOUS SPRAY, HYDROCORTISONE LOTION, HYDROCORTISONE ACETATE, ANTI ITCH, ANTI-ITCH, COOL RELIEF GEL WITH ALOE, HYDROCORTISONE SPRAY, DRS. HYDROCORTISONE, HYDROCORTISONE, ANTIPRURITIC (ANTI-ITCH), ANTI-ITCH CREAM, HYDROCORTISONE CREAM, HYDROCORTISONE 1%, HYDROCORTISONE CREAM 1%, ANTI-PRURITIC, HYDROCORTISONE CONTINUOUS SPRAY, HYDROCORTISONE LOTION, HYDROCORTISONE ACETATE, ANTI ITCH, ANTI-ITCH, COOL RELIEF GEL WITH ALOE, HYDROCORTISONE SPRAY, DRS. HYDROCORTISONE, HYDROCORTISONE, ANTIPRURITIC (ANTI-ITCH), ANTI-ITCH CREAM, HYDROCORTISONE CREAM, HYDROCORTISONE 1%, HYDROCORTISONE CREAM 1%, ANTI-PRURITIC, HYDROCORTISONE CONTINUOUS SPRAY, HYDROCORTISONE LOTION, HYDROCORTISONE ACETATE, ANTI ITCH, ANTI-ITCH, COOL RELIEF GEL WITH ALOE, HYDROCORTISONE SPRAY, DRS. HYDROCORTISONE, HYDROCORTISONE, ANTIPRURITIC (ANTI-ITCH), ANTI-ITCH CREAM, HYDROCORTISONE CREAM, HYDROCORTISONE 1%, HYDROCORTISONE CREAM 1%, ANTI-PRURITIC, HYDROCORTISONE CONTINUOUS SPRAY, HYDROCORTISONE LOTION, HYDROCORTISONE ACETATE, ANTI ITCH, ANTI-ITCH, COOL RELIEF GEL WITH ALOE, HYDROCORTISONE SPRAY, DRS. HYDROCORTISONE, HYDROCORTISONE, ANTIPRURITIC (ANTI-ITCH), ANTI-ITCH CREAM, HYDROCORTISONE CREAM, HYDROCORTISONE 1%, HYDROCORTISONE CREAM 1%, ANTI-PRURITIC, HYDROCORTISONE CONTINUOUS SPRAY, HYDROCORTISONE LOTION, HYDROCORTISONE ACETATE, ANTI ITCH, ANTI-ITCH, COOL RELIEF GEL WITH ALOE, HYDROCORTISONE SPRAY, DRS. HYDROCORTISONE, APREMILAST, HYDROXYCHLOROQUINE, HYDROXYCHLOROQUINE, DOXYCYCLINE HYCLATE, DOXYCYCLINE, DOXYCLYCLINE HYCLATE, MYCOPHENOLATE MOFETIL, MYCOPHENOLATE MOFETIL HYDROCHLORIDE, CANDESARTAN, DICLOFENAC SODIUM, DICLOFENAC SODIUM TOPICAL, DICLOFENAC SODIUM TOPICAL GEL, 1%, DICLOFENAC, DICLOFENAC SODIUM 1%, DICLOFENAC POTASSIUM, DICLOFENAC POTASSIUM, FILM COATED, DICLOFENAC POTASSIUM TABLETS, LEFLUNOMIDE, METHOTREXATE, METHOTREXATE SODIUM, METHOTREXATE, METHOTREXATE SODIUM, METHOTREXATE, METHOTREXATE SODIUM, METHOTREXATE, METHOTREXATE SODIUM, METHOTREXATE, METHOTREXATE SODIUM, METHOTREXATE, METHOTREXATE SODIUM, METHOTREXATE, METHOTREXATE SODIUM, METHOTREXATE, METHOTREXATE SODIUM, METHOTREXATE, METHOTREXATE SODIUM, METHOTREXATE, METHOTREXATE SODIUM, METHOTREXATE, METHOTREXATE SODIUM, METHOTREXATE, METHOTREXATE SODIUM, METHOTREXATE, METHOTREXATE SODIUM, METHOTREXATE, METHOTREXATE SODIUM, METHOTREXATE, METHOTREXATE SODIUM, METHOTREXATE, METHOTREXATE SODIUM, METHOTREXATE, METHOTREXATE SODIUM, METHOTREXATE, METHOTREXATE SODIUM, METHOTREXATE, METHOTREXATE SODIUM, METHOTREXATE, METHOTREXATE SODIUM, METHOTREXATE, METHOTREXATE SODIUM, METHOTREXATE, METHOTREXATE SODIUM, METHOTREXATE, METHOTREXATE SODIUM, METHOTREXATE, METHOTREXATE SODIUM, METHOTREXATE, METHOTREXATE SODIUM, METHOTREXATE, METHOTREXATE SODIUM, METHOTREXATE, METHOTREXATE SODIUM, METHOTREXATE, METHOTREXATE SODIUM, METHOTREXATE, METHOTREXATE SODIUM, METHOTREXATE, METHOTREXATE SODIUM, METHOTREXATE, METHOTREXATE SODIUM, METHOTREXATE, METHOTREXATE SODIUM, METHOTREXATE, METHOTREXATE SODIUM, METHOTREXATE, METHOTREXATE SODIUM, METHOTREXATE, METHOTREXATE SODIUM, METHOTREXATE, METHOTREXATE SODIUM, METHOTREXATE, METHOTREXATE SODIUM, METHOTREXATE, METHOTREXATE SODIUM, METHOTREXATE, METHOTREXATE SODIUM, GOLIMUMAB, ADALIMUMAB, ADALIMUMAB-AATY, ADALIMUMAB-ADAZ, ADALIMUMAB-FKJP, NAPROXEN SODIUM, NAPROXEN SODIUM 220MG, NAPROXEN SODIUM, COATED TABLETS, NAPROXEN SODIUM TABLET, COATED, NAPROXEN SODIUM, NAPROXEN SODIUM 220MG, NAPROXEN SODIUM, COATED TABLETS, NAPROXEN SODIUM TABLET, COATED, NAPROXEN SODIUM, NAPROXEN SODIUM 220MG, NAPROXEN SODIUM, COATED TABLETS, NAPROXEN SODIUM TABLET, COATED, NAPROXEN SODIUM, NAPROXEN SODIUM 220MG, NAPROXEN SODIUM, COATED TABLETS, NAPROXEN SODIUM TABLET, COATED, NAPROXEN SODIUM, NAPROXEN SODIUM 220MG, NAPROXEN SODIUM, COATED TABLETS, NAPROXEN SODIUM TABLET, COATED, CERTOLIZUMAB PEGOL, CERTOLIZUMAB PEGOL, CERTOLIZUMAB PEGOL, PHENYLEPHRINE HYDROCHLORIDE, APREPITANT, PANTOPRAZOLE SODIUM, PANTOPRAZOLE, PANTOPRAZOLE SODIUM IN 0.9% SODIUM CHLORIDE, PANTOPRAZOLE SODIUM INJECTION, LANSOPRAZOLE, TOPIRAMATE, TOPIRAMATE SPINKLE, TOPIRAMATE, TOPIRAMATE SPINKLE, ERENUMAB-AOOE, PREDNISONE, PREDNISONE, PREDNISONE, PREDNISONE, CALCIUM GLUCONATE, ISOPROPYL ALCOHOL, 70%ISOPROPYL ALCOHOL, ALCOHOL PREP PADS, ALCOHOL, ISOPROPYL ALCOHOL SPRAY, SULFASALAZINE, SULFASALAZINE, SULFASALAZINE, SULFASALAZINE, SULFASALAZINE, SULFASALAZINE, SULFASALAZINE, SULFASALAZINE, SULFASALAZINE, SULFASALAZINE, SULFASALAZINE, SULFASALAZINE, SULFASALAZINE, SULFASALAZINE, SULFASALAZINE, PREGABALIN, ALENDRONATE SODIUM, ADALIMUMAB-ADAZ, PREDNISOLONE, PREDNISOLONE ORAL, PREDNISOLONE ORAL SOLUTION, ERGOCALCIFEROL, RAMIPRIL, MELOXICAM, LORAZEPAM, PIROXICAM, SULFASALAZINE, RISEDRONATE SODIUM, CYANOCOBALAMIN, LISINOPRIL, MAGNESIUM CARBONATE, LEVOTHYROXINE SODIUM, LEVOTHYROXINE SODIUM ANHYDROUS, ERGOCALCIFEROL, |
||||
| 274 | 26526761 |
US |
1 | |
Feeling abnormal, Fatigue, Product use issue, Therapy interrupted, Product use in unapproved indication, |
||||
CALCIUM, MAGNESIUM, POTASSIUM, AND SODIUM OXYBATES, |
||||
| 275 | 26526766 |
US |
2 | |
Yellow skin, Depersonalisation/derealisation disorder, Fatigue, Dizziness, Headache, Therapy interrupted, Product use issue, Inability to afford medication, |
||||
DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE, DEXTROAMPHETAMINE SULFATE, AND AMPHETAMINE SULFATE, DEXTROAMPHETAMINE SULFATE, DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE SULFATE AND AMPHETAMINE ASPARTATE, DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE, DEXTROAMPHETAMINE SULFATE, AND AMPHETAMINE SULFATE, DEXTROAMPHETAMINE SULFATE, DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE SULFATE AND AMPHETAMINE ASPARTATE, SERTRALINE, SERTRALINE, MELOXICAM, STANDARDIZED SENNA CONCENTRATE, PSYLLIUM HUSK, |
||||
| 276 | 26528524 |
66 | 2 | |
Product use issue, Malaise, |
||||
ELVITEGRAVIR, COBICISTAT, EMTRICITABINE, AND TENOFOVIR ALAFENAMIDE, ALBUTEROL SULFATE, RILONACEPT, COLCHICINE, DIPHENHYDRAMINE, DIPHENHYDRAMINE HYDROCHLORIDE, INDOMETHACIN, OMEPRAZOLE, OMEPRAZOLE MAGNESIUM, ONDANSETRON HYDROCHLORIDE, ONDANSETRON, ONDANSETRON TABLETS, TACROLIMUS, TACROLIMUS OINTMENT 0.1%, TACROLIMUS EXTENDED-RELEASE CAPSULES, VALACYCLOVIR, VALACYCLOVIR HYDROCHLORIDE, RILONACEPT, |
||||
| 277 | 26528875 |
60 | 2 | |
Knee arthroplasty, Vascular operation, Loss of consciousness, Fall, Back injury, Spinal column injury, Therapy interrupted, Product use issue, |
||||
BELIMUMAB, |
||||
| 278 | 26522040 |
CA |
66 | 1 |
Cardiac disorder, Product dose omission issue, Off label use, Product use issue, |
||||
PATIROMER, |
||||
| 279 | 26522431 |
US |
37 | 2 |
Migraine, Product use issue, |
||||
FREMANEZUMAB-VFRM, FREMANEZUMAB-VFRM, |
||||
| 280 | 26521244 |
US |
2 | |
Exposure during pregnancy, Off label use, Product use issue, |
||||
CABOTEGRAVIR AND RILPIVIRINE, CABOTEGRAVIR AND RILPIVIRINE, |
||||
| 281 | 26521519 |
US |
7 | 2 |
Lactic acidosis, Product use issue, Insurance issue, Iron deficiency, Vitamin D deficiency, Gastrointestinal microorganism overgrowth, Gastrooesophageal reflux disease, Weight decreased, |
||||
TEDUGLUTIDE, TEDUGLUTIDE, TEDUGLUTIDE, TEDUGLUTIDE, FERROUS SULFATE, FERROUS SULFATE, METRONIDAZOLE, METRONIDAZOLE TOPICAL, CYANOCOBALAMIN, CYANOCOBALAMIN, SODIUM BICARBONATE, SODIUM BICARBONATE INJECTION,, CHOLESTYRAMINE, CIPROFLOXACIN HYDROCHLORIDE, |
||||
| 282 | 26521542 |
US |
2 | |
Lip discolouration, Lip pain, Product use issue, Lip swelling, |
||||
TIRZEPATIDE, TIRZEPATIDE, |
||||
| 283 | 26521708 |
EU |
72 | |
Death, Diffuse large B-cell lymphoma recurrent, B-lymphocyte count decreased, Cell marker decreased, Product use issue, |
||||
RITUXIMAB, RITUXIMAB, CYCLOPHOSPHAMIDE FOR INJECTION, CYCLOPHOSPHAMIDE, CYCLOPHOSPHAMIDE INJECTION, SOLUTION, CYCLOPHOSPHAMIDE FOR INJECTION, CYCLOPHOSPHAMIDE, CYCLOPHOSPHAMIDE INJECTION, SOLUTION, DOXORUBICIN HYDROCHLORIDE, DOXORUBICIN, DOXORUBICIN HYDROCHLORIDE, DOXORUBICIN, LENALIDOMIDE, LONCASTUXIMAB TESIRINE, POLATUZUMAB VEDOTIN, POLATUZUMAB VEDOTIN, PREDNISONE, PREDNISONE, TOCILIZUMAB, |
||||
| 284 | 26517266 |
US |
1 | |
Urinary tract infection, Drug ineffective, Hypoproteinaemia, Product use issue, |
||||
ECULIZUMAB, |
||||
| 285 | 26517385 |
58 | ||
Blood glucose increased, Product use issue, Device mechanical issue, |
||||
INSULIN GLARGINE-YFGN, INSULIN GLARGINE, INSULIN GLARGINE-YFGN, INSULIN GLARGINE, |
||||
| 286 | 26517416 |
US |
2 | |
Exposure during pregnancy, Off label use, Product use issue, |
||||
CABOTEGRAVIR AND RILPIVIRINE, CABOTEGRAVIR AND RILPIVIRINE, CABOTEGRAVIR AND RILPIVIRINE, |
||||
| 287 | 26517512 |
55 | ||
Glycosylated haemoglobin increased, Device delivery system issue, Device breakage, Device mechanical issue, Product use issue, |
||||
| 288 | 26517517 |
52 | ||
Blood glucose increased, Product use issue, Device mechanical issue, |
||||
| 289 | 26517621 |
US |
1 | |
Product use issue, |
||||
PIMAVANSERIN TARTRATE, |
||||
| 290 | 26517691 |
US |
70 | 2 |
Infusion site haemorrhage, Infusion site pain, Product adhesion issue, Product use issue, |
||||
TREPROSTINIL, TREPROSTINIL, OMEPRAZOLE, OMEPRAZOLE MAGNESIUM, VALACYCLOVIR, VALACYCLOVIR HYDROCHLORIDE, MYCOPHENOLATE MOFETIL, MYCOPHENOLATE MOFETIL HYDROCHLORIDE, POTASSIUM CHLORIDE, POTASSIUM CHLORIDE EXTENDED-RELEASE, POTASSIUM CHLORIDE, DEXTROSE MONOHYDRATE, POTASSIUM CHLORIDE ORAL, PREDNISONE, SODIUM CHLORIDE, SODIUM CHLORIDE TABLET, SODIUM CHLORIDE TABLETS, MACITENTAN, ALBUTEROL SULFATE, HYDROXYCHLOROQUINE SULFATE, FLUTICASONE PROPIONATE, FLUTICASONE PROPIONATE NASAL, MONTELUKAST SODIUM, MONTELUKAST, OXYGEN, 0XYGEN, CETIRIZINE HCL, CETIRIZINE, FUROSEMIDE, FLUTICASONE PROPIONATE AND SALMETEROL, ACETAMINOPHEN, GUAIFENESIN, AND PHENYLEPHRINE HYDROCHLORIDE, ACETAMINOPHEN, |
||||
| 291 | 26517809 |
US |
66 | 1 |
Inability to afford medication, Insurance issue, Product use issue, Therapy interrupted, |
||||
| 292 | 26517976 |
EU |
16 | 2 |
Intentional overdose, Nausea, Abdominal pain, Suicide attempt, Product use issue, |
||||
ACETAMINOPHEN, ACETAMINOPHEN 500MG, ACETAMINOPHEN TABLET EXTENDED RELEASE, PAIN RELIEVER, |
||||
| 293 | 26517989 |
ZA |
14 | 2 |
Liver injury, Pancreatitis, Type IV hypersensitivity reaction, Product use issue, Product administered to patient of inappropriate age, |
||||
| 294 | 26518005 |
EU |
14 | 2 |
Suicide attempt, Intentional overdose, Product use issue, Nausea, Abdominal pain, |
||||
ACETAMINOPHEN, ACETAMINOPHEN 500MG, ACETAMINOPHEN TABLET EXTENDED RELEASE, PAIN RELIEVER, |
||||
| 295 | 26518006 |
EU |
||
Cardiac failure, Multiple fractures, Hip fracture, Rib fracture, Fall, Hyponatraemia, Product use issue, |
||||
SELINEXOR, POMALIDOMIDE, DEXAMETHASONE, DEXAMETHASONE 1.5 MG, |
||||
| 296 | 26518020 |
US |
||
Insurance issue, Product use issue, Off label use, |
||||
| 297 | 26518116 |
GB |
||
Stridor, Periorbital oedema, Product use issue, |
||||
SEVOFLURANE, FENTANYL, PROPOFOL, ONDANSETRON HYDROCHLORIDE, ONDANSETRON, ONDANSETRON TABLETS, ACETAMINOPHEN, ACETAMINOPHEN 500MG, ACETAMINOPHEN TABLET EXTENDED RELEASE, PAIN RELIEVER, TRANEXAMIC ACID, MORPHINE, PREDNISOLONE, PREDNISOLONE ORAL, PREDNISOLONE ORAL SOLUTION, MYCOPHENOLATE MOFETIL, MYCOPHENOLATE MOFETIL HYDROCHLORIDE, OMEPRAZOLE, OMEPRAZOLE MAGNESIUM, |
||||
| 298 | 26518122 |
US |
63 | 2 |
Product use issue, |
||||
TREPROSTINIL, TREPROSTINIL, TREPROSTINIL, AMBRISENTAN, FUROSEMIDE, FLUTICASONE FUROATE AND VILANTEROL TRIFENATATE, ALBUTEROL SULFATE, LORAZEPAM, SILDENAFIL CITRATE, |
||||
| 299 | 26518272 |
US |
2 | |
Abdominal discomfort, Swelling, Product use issue, |
||||
SULFAMETHOXAZOLE AND TRIMETHOPRIM, |
||||
| 300 | 26518302 |
EU |
16 | 1 |
Intentional overdose, Abdominal pain, Product use issue, Headache, Suicide attempt, |
||||
ACETAMINOPHEN, ACETAMINOPHEN 500MG, ACETAMINOPHEN TABLET EXTENDED RELEASE, PAIN RELIEVER, |
||||
disclaimer
Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated. We may limit or otherwise restrict your access to the API in line with our Terms of Service.
terms
license
last_updated
2026-04-28